| Literature DB >> 30043438 |
Kayo Kayahashi1, Yasunari Mizumoto1, Subaru Myojo1, Yusuke Mitani2, Atsushi Tajima3, Hiroshi Fujiwara1.
Abstract
Recent reports showed that neoadjuvant chemotherapy (NAC) has been successfully applied to treat advanced uterine cervical cancers during pregnancy. However, its side effects on the fetus remain unclear. Here, we report a 33-year-old primipara who underwent four courses of NAC therapy, paclitaxel and cisplatin, from 17 to 27 weeks of gestation due to uterine cervical cancer stage IB2. At 31 weeks of gestation, cesarean section and radical hysterectomy were performed, and a female baby weighing 1446 g was born. Although pre- and postnatal courses were uneventful, neonatal erythroderma over the entire body was observed just after delivery. The pathological diagnosis was ichthyosiform erythroderma, which was later demonstrated to be keratitis-ichthyosis-deafness syndrome, by exome sequencing analysis. Although her skin disorder was consistent with keratitis-ichthyosis-deafness syndrome, the skin condition gradually improved after delivery. These findings suggest that NAC therapy during pregnancy might cause or exacerbate systemic skin lesions in the fetus/neonate.Entities:
Keywords: cervical cancer; neoadjuvant chemotherapy; neonatal erythroderma; pregnancy
Mesh:
Substances:
Year: 2018 PMID: 30043438 DOI: 10.1111/jog.13746
Source DB: PubMed Journal: J Obstet Gynaecol Res ISSN: 1341-8076 Impact factor: 1.730